Prometic reports Phase II/III data for Ryplazym in congenital plasminogen deficiency

Prometic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) reported data from a Phase II/III trial showing that there was no recurrence of lesions among 10 patients with congenital plasminogen deficiency who received IV Ryplazym every 2, 3 or 4 days for 48 weeks. Additionally, there were no safety or tolerability issues observed with long-term treatment with the human plasma-derived purified plasminogen formulated for IV use.

Prometic previously reported 12-week data from the trial showing that Ryplazym met the primary endpoint of ≥80% of patients achieving target plasminogen trough levels for ≥3 measurements. Specifically, all 10 patients achieved target plasminogen levels after 12 weeks...